Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.

[Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología].

Castiñeiras Fernández J, Cozar Olmo JM, Fernández-Pro A, Martín JA, Brenes Bermúdez FJ, Naval Pulido E, Molero JM, Pérez Morales D; (Sociedad Española de Médicos de Atención Primaria; Sociedad Española de Medicina General; Sociedad Española de Medicina de Familia y Comunitaria; Asociación Española de Urología.

Actas Urol Esp. 2010 Jan;34(1):24-34. Spanish.

PMID:
20223130
2.

[Referral criteria for benign prostatic hyperplasia in primary care].

Molero JM, Pérez Morales D, Brenes Bermúdez FJ, Naval Pulido E, Fernández-Pro A, Martín JA, Castiñeiras Fernández J, Cozar Olmo JM.

Aten Primaria. 2010 Jan;42(1):36-46. doi: 10.1016/j.aprim.2009.07.006. Epub 2009 Nov 14. Spanish.

3.

[Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].

Fourcade RO, Picot MC, Gaudin AF, Texier N, Slama A.

Presse Med. 2007 May;36(5 Pt 1):755-63. Epub 2007 Feb 27. French.

PMID:
17329070
4.

[Urine incontinence referral criteria for primary care].

Brenes Bermúdez FJ, Cozar Olmo JM, Esteban Fuertes M, Fernández-Pro Ledesma A, Molero García JM; Sociedad Española de Médicos de Atención Primaria; Sociedad Española de Médicos Generales y de Familia; Sociedad Española de Medicina de Familia y Comunitaria; Asociación Española de Urología.

Aten Primaria. 2013 May;45(5):263-73. doi: 10.1016/j.aprim.2013.01.017. Epub 2013 Apr 25. Spanish.

5.

[Urine incontinence referral criteria for primary care].

Brenes Bermúdez FJ, Cozar Olmo JM, Esteban Fuertes M, Fernández-Pro Ledesma A, Molero García JM.

Semergen. 2013 May-Jun;39(4):197-207. doi: 10.1016/j.semerg.2012.11.005. Epub 2013 Jan 30. Spanish.

PMID:
23726731
7.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group.

Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.

PMID:
19013011
8.

Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.

Logan YT, Belgeri MT.

Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. Review.

PMID:
16129387
9.

Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.

Pinto F, Racioppi M, Sacco E, Totaro A, Brescia A, Volpe A, Gardi M, Bassi PF.

Arch Ital Urol Androl. 2009 Mar;81(1):1-8. Review.

PMID:
19499750
10.

[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].

Descazeaud A, Robert G, Delongchamps NB, Cornu JN, Saussine C, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Azzouzi AR, Faix A, Desgrandchamps F, de la Taille A; Comité des troubles mictionnels de l’homme de l’association française d’urologie.

Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. French.

PMID:
23178093
11.

Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.

Carballido J, Fourcade R, Pagliarulo A, Brenes F, Boye A, Sessa A, Gilson M, Castro R.

Int J Clin Pract. 2011 Sep;65(9):989-96. doi: 10.1111/j.1742-1241.2011.02735.x. Epub 2011 Jul 7.

PMID:
21733048
12.

Diagnosis and management of benign prostatic hyperplasia.

Edwards JL.

Am Fam Physician. 2008 May 15;77(10):1403-10. Review.

13.

5alpha-reductase inhibitors: what role should they play?

Kaplan SA.

Urology. 2001 Dec;58(6 Suppl 1):65-70; discussion 70. Review.

PMID:
11750255
15.

Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary.

Spatafora S, Conti G, Perachino M, Casarico A, Mazzi G, Pappagallo GL; AURO.it BPH Guidelines Committee.

Curr Med Res Opin. 2007 Jul;23(7):1715-32.

PMID:
17588302
16.
17.

Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.

Magri V, Trinchieri A, Montanari E, Del Nero A, Mangiarotti B, Zirpoli P, de Eguileor M, Marras E, Ceriani I, Vral A, Perletti G.

Arch Ital Urol Androl. 2007 Jun;79(2):84-92.

PMID:
17695414
18.
19.
Items per page

Supplemental Content

Write to the Help Desk